<DOC>
	<DOCNO>NCT00127140</DOCNO>
	<brief_summary>The primary purpose trial determine maximum tolerate dose ( MTD ) , maximum acceptable dose ( MAD ) evaluate dose limit toxicity ( DLT ) oral vorinostat patient malignant lymphoma .</brief_summary>
	<brief_title>A Study Oral Suberoylanilide Hydroxamic Acid ( SAHA ) Patients With Malignant Lymphoma ( 0683-030 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients relapse complete partial response , ineffective previous chemotherapy Patients history chemotherapy , antibody therapy , radiotherapy , previous 4 week ( 6 month radioisotopelabeled antibody ) Any uncontrolled concomitant illness Are pregnant breastfeed Serious drug food allergy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>